Voyager Therapeutics outlines pivotal 2026 milestones: tau programs, capsid validation, NeuroShuttle data

Voyager Therapeutics, Inc.

Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.
VY7523 anti-tau antibody trial fully enrolled; tau PET imaging data expected H2 2026.
Neurocrine plans to initiate clinical trial with NBIB-‘223 for Friedreich's ataxia in 2026.
ALPL-NeuroShuttle shows similar target engagement to TfR shuttle with more sustained brain exposure; partnering interest strong.
Four wholly owned and partnered IV-delivered neuro gene therapy programs advanced to preclinical toxicology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.